VBK - Vanguard Small-Cap Growth ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD

179.58

-0.57 (-0.32%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	180.15
Open	181.23
Bid	0.00 x 1200
Ask	0.00 x 800
Day's Range	179.45 - 181.44
52 Week Range	141.75 - 182.77
Volume	158,381
Avg. Volume	151,909

Net Assets	22.95B
NAV	173.92
PE Ratio (TTM)	N/A
Yield	0.70%
YTD Return	8.29%
Beta (3y)	1.04
Expense Ratio (net)	0.07%
Inception Date	2004-01-26

Trade prices are not sourced from all markets

Business Wire4 days ago
E*TRADE Adds Several of Today’s Most Popular ETFs to Commission-Free ETF Lineup
E*TRADE Financial Corporation today announced it has surpassed 250 commission-free ETFs with the addition of 46 ETFs from six providers to its Commission-Free ETF Pr
Zacks6 days ago
Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar?
Style Box ETF report for FYC
InvestorPlacelast month
5 Small-Cap ETFs With Big-Time Upside Potential
Small-cap stocks and the corresponding exchange traded funds (ETFs) are on a tear. Over the past week, the widely followed Russell 2000 index is up nearly 3%, bringing its year-to-date gain to over 7%. By comparison, the large-cap S&P 500 is up just over 3% this year.
Zackslast month
Is Guggenheim S&P SmallCap 600 Pure Growth ETF (RZG) a Hot ETF Right Now?
Smart Beta ETF report for RZG
Zackslast month
Should Vanguard S&P Small-Cap 600 Growth ETF (VIOG) Be on Your Investing Radar?
Style Box ETF report for VIOG
Market Realistlast month
Analyzing BEAT, SUPN, ADBE And RHT Stocks
BioTelemetry’s (BEAT) net income has declined at a 3-year and 5-year average of 17% and 5.9% respectively. The company’s negative pre-tax margin changed from 5.5% in 2013 to 3.6% in 2017. The stock prices have beaten the diagnostics & research industry and S&P 500 between 2013 and 2017. The market cap had gained 373% between 2013 and 2017.
InvestorPlacelast month
5 Market-Beating Small-Cap ETFs Trading at New Highs
Wall Street has been on a roller-coaster ride this year. Yet, the small-cap segment of the broader market has been outperforming, defying extremely volatility. This is especially true as the Russell 2000 is nearing its record levels with just less than 1% away from its peak.Source: ShutterstockWhy Small Caps?
Zackslast month
Small-Cap ETF (VBK) Hits New 52-Week High
This small cap ETF hits a new 52-week high. Are more gains in store for this ETF?
Zackslast month
Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar?
Style Box ETF report for FYC
Zacks2 months ago
Should Guggenheim S&P SmallCap 600 Pure Growth ETF (RZG) Be on Your Investing Radar?
Style Box ETF report for RZG
ETF Trends4 months ago
Big Growth With Popular Small-Cap ETF
Small-cap stocks and the related exchange traded funds are often prized for their growth prospects and small-cap ETFs are explicitly dedicated to the growth factor, including the popular Vanguard Small-Cap ...
InvestorPlace4 months ago
7 of the Best Growth ETFs
Although stocks have recently given back some of their short-term gains, the market big picture remains within the frame of momentum, which makes for a good environment to look to growth exchange-traded funds (ETFs).
Zacks5 months ago
The Zacks Analyst Blog Highlights: Select Sector SPDR Technology, Vanguard Small-Cap Growth, iShares MSCI ACWI, EventShares U.S. Tax Reform and Vanguard Value
The Zacks Analyst Blog Highlights: Select Sector SPDR Technology, Vanguard Small-Cap Growth, iShares MSCI ACWI, EventShares U.S. Tax Reform and Vanguard Value
Zacks5 months ago
Amazing ETF Strategies for Skyrocketing Markets
We have highlighted some investing ideas that could prove extremely beneficial for investors this year in the bullish market.
Market Realist5 months ago
How Is Bioverativ’s Eloctate Positioned Now?
A Snapshot of Bioverativ's Recent Performance
InvestorPlace6 months ago
ETFs to Bet on the Final Tax Bill: What’s Hot, What’s Not
After negotiating on two versions of the bill already passed by the House and Senate, Republicans unveiled their final tax bill — which would reshape the tax code in three decades, making America more competitive. The Congress will vote on the legislation on Tuesday and sent it to President Donald Trump for his signature by the end of the year.Source: Shutterstock
Zacks7 months ago
The Zacks Analyst Blog Highlights: Vanguard Small-Cap Growth, iShares S&P Small-Cap 600 Growth and Vanguard S&P Small-Cap 600 Growth
The Zacks Analyst Blog Highlights: Vanguard Small-Cap Growth, iShares S&P Small-Cap 600 Growth and Vanguard S&P Small-Cap 600 Growth
Zacks7 months ago
3 Small-Cap Growth ETFs Surging to #1 Rank on Holiday Fervor
Small caps are the biggest beneficiaries of Trump???s tax cut plans and the booming economy.
InvestorPlace7 months ago
7 Vanguard ETFs to Build a Total Portfolio
When you’re putting together a portfolio — whether you’re starting one tomorrow, or you’re looking to tinker with what you’ve got — there are a few basics that most investors aim for: U.S. stocks. International holdings. Fixed income.
Zacks8 months ago
ETFs to Benefit from Trump Tax Plan
These ETFs will likely gain traction if Trump's tax plans see the day of light soon.
Investor's Business Daily9 months ago
Dow, S&P Hit Record Highs; Trump Plan Ignites Small-Cap Stocks
Key U.S. stock indexes turned mixed Monday even as small caps and biotechs continued to rally.
Zacks9 months ago
Hot Areas of Last Week and Their ETFs
Hopes for Trump's tax reforms, abating North Korea fears, lower-than-expected damage from Hurricane Irma and record stock market highs rekindled the love for U.S. equity ETFs last week.
ETF Trends9 months ago
Small-Cap ETFs for a More Risk-On Investor
Small-capitalization stock investors were defensive going into the 2017, but they have quickly changed their tune, turning to more growth-weighted smaller company picks. Investors can also gain diversified ...
Market Realist9 months ago
Nuplazid for Long-Term Care: Revenue Driver for Acadia?
Acadia Pharmaceuticals (ACAD) plans to focus on long-term care (or LTC) facilities to boost Nuplazid’s adoption in the Parkinson’s disease (or PD) psychosis indication.
Market Realist11 months ago
Bioverativ’s Eloctate Sees More Demand from Hemophilia A Patients
In 1Q17, Bioverativ’s Eloctate witnessed revenues close to $155.9 million, which is about $48.0 million more YoY (year-over-year).